XML 164 R101.htm IDEA: XBRL DOCUMENT v3.25.1
Revenues and other income - Additional Information (Details)
$ in Thousands
 1 Months Ended 12 Months Ended
Dec. 04, 2023
USD ($)
Nov. 07, 2023
USD ($)
Jul. 07, 2023
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2024
EUR (€)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Dec. 31, 2021
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2021
EUR (€)
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenue         € (7,191,000)   € 36,207,000 € 4,776,000      
Current contract liabilities         18,100,000   18,100,000        
Current contract assets         0   2,062,000        
Capital increases         0   60,154,000 0      
Refund liabilities         35,613,000   0        
Other income         4,419,000   6,150,000 4,776,000      
Revenues         € (11,609,000)   30,058,000 0      
Research tax credit utilization period         3 years 3 years          
Trade receivables         € 2,977,000   905,000        
Research tax credit         3,300,000   3,900,000        
Subsidies         89,000   229,000 135,000      
Net loss for the period         68,132,000   39,700,000        
Services                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues         (17,534,000)   29,750,000 0      
Other sales                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues         5,924,000   308,000 0      
Janssen                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Collaboration agreement, upfront payment license fee | $     $ 30,000                
Collaboration agreement, success-based payment | $     1,800,000                
Proceeds receivable due to milestone completion | $                   $ 20,000  
Capital increases | $     30,000                
Revenues         (1,600,000)   (1,600,000)        
Janssen | Services                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues         (23,400,000)   29,600,000        
Net loss for the period         19,300,000            
Janssen | Research and Development                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues         (4,000,000)            
Janssen | Technology transfer                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Refund liabilities         35,600,000            
Revenues         (1,800,000)   100,000        
Janssen | Other sales                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Revenues         € 5,900,000   300,000        
Janssen | Tranche one                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Capital increases | $           $ 5,000          
Janssen | Tranche two                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Capital increases | $ $ 4,800 $ 20,200       $ 25,000          
Janssen | Top of Range                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Potential development and commercial milestones payments | $     650,000                
Collaboration agreement, compensation per indication | $     220,000                
Janssen | Top of Range | Nanobiotix Corp.                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Collaboration agreement, compensation per indication | $     $ 220,000                
LianBio, NBTXR3                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Current contract liabilities                     € 16,500,000
Minimum threshold to provide additional know-how to third party under collaboration agreement         80.00% 80.00%          
Collaboration agreement, amount collected         € 1,100,000            
Upfront payment received | $       $ 20,000         $ 20,000    
Trade receivables             300,000        
Supply Services         1,000,000   2,000,000 € 500,000      
LianBio, NBTXR3 | Maximum                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Potential development and commercial milestones payments | $       $ 205,000              
LianBio, NBTXR3 and Cetuximab                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Collaboration agreement, amount collected             334,300        
Other income         237,000   € 1,600,000        
Global Trial Clinical Agreement                      
Disclosure of disaggregation of revenue from contracts with customers [line items]                      
Other income         € 778,000